What is Aura?
Aura Biosciences is a pioneering clinical-stage biotechnology company dedicated to the development of a novel technology platform based on virus-like drug conjugates (VDCs). This innovative approach is designed to target and destroy cancer cells with high precision while simultaneously activating the immune system to foster long-lasting anti-tumor immunity. By focusing on the intersection of virology and oncology, the company aims to redefine the standard of care for patients facing challenging cancer diagnoses.
The company's market position is bolstered by a robust intellectual property portfolio and a clear focus on therapeutic innovation. Aura's commitment to scientific excellence and its ability to attract high-caliber institutional backing have enabled it to transition from early-stage research into advanced clinical trials, marking it as a significant player in the global biotech landscape.
How much funding has Aura raised?
Aura has raised a total of $345.9M across 13 funding rounds:
Private Equity
$4M
Series B
$21M
Debt
$11.5M
Series C
$30M
Series D
$40M
Other Financing Round
$80M
Stock Offering
$76M
Stock/Share Issuance
$69.9M
Private Equity (2014): $4M, investors not publicly disclosed
Series B (2015): $21M led by LI-COR Biosciences, Ysios Capital, Chiesi Ventures, and Advent Life Sciences
Debt (2016): $11.5M supported by Ysios Capital, Chiesi Ventures, and Alexandria Venture Investments
Series C (2017): $30M featuring Ysios Capital, Lundbeckfonden Ventures, Arix Bioscience, LI-COR Biosciences, Advent Life Sciences, The estate of Henri Termeer, Alexandria Venture Investments, Chiesi Ventures, and Columbus Venture Partners SGEIC
Series D (2019): $40M backed by Medicxi
Other Financing Round (2021): $80M with participation from Velosity Capital, Ysios Capital, Adage Capital Management, Columbus Venture Partners S.G.E.I.C, Lundbeckfonden Ventures, Arix Bioscience, Surveyor Capital, Chiesi Ventures, Medicxi, Matrix Capital Management, Rock Springs Capital, and Advent Life Sciences
Stock Issuance/Offering (2021): $76M, investors not publicly disclosed
Stock/Share Issuance (2025): $69.9M, investors not publicly disclosed
Key Investors in Aura
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on novel therapies for high unmet medical needs.
Chiesi Ventures
Chiesi Ventures is a venture capital firm dedicated to investing in early-stage development opportunities focused on rare and orphan disorders, collaborating with universities and entrepreneurial companies to accelerate research.
Alexandria Venture Investments
Alexandria Venture Investments is the strategic investment arm of Alexandria Real Estate Equities, focusing on the life sciences industry by supporting biotechnology and translational research entities.
What's next for Aura?
With the recent strategic investment, Aura Biosciences is poised to enter a pivotal phase of its corporate lifecycle. The company is expected to prioritize the advancement of its lead clinical programs, focusing on data readout and regulatory milestones that will determine the future commercial viability of its VDC platform. Strategic efforts will likely center on scaling operational capabilities and expanding its research footprint to support late-stage development.
Furthermore, the continued support from a syndicate of specialized life sciences investors suggests a long-term commitment to the company's mission. As Aura moves forward, the focus will remain on demonstrating the clinical efficacy and safety of its therapeutic candidates, potentially setting the stage for future partnerships or strategic exits within the competitive oncology market.
